Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Gov't Plans To Control COVID Vaccine Distribution At Least Through 2022; Already Authorized Products Have Booster Advantage

Executive Summary

Due to need to plan for potential vaccine boosters now, administration is focusing on contracting with the companies whose shots are already being given in the US, David Kessler tells the Senate health committee. Data on whether it is ok to ‘mix and match’ vaccine types with boosters should be available in a few months.

You may also be interested in...



To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge

Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.

COVID-19 Vaccines: Declining Antibody Levels, Breakthrough Infections Could Spur Booster Recommendations

Although data to support use of booster doses currently are lacking, members of the US CDC's Advisory Committee on Immunization Practices suggest potential triggers for recommending revaccination after the primary series.

Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide

BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel